Regeneron Pharmaceuticals witnessed a mix of activities lately, with acquisitions such as
Diversified Trust Co and
Global Assets Advisory acquiring shares, and
Envestnet Portfolio Solutions and Loring
Wolcott & Coolidge Fiduciary Advisors
reducing positions. Despite lowered price targets by
UBS and
JPMorgan, others such as
Adams Diversified Equity Fund made significant holdings, and Janney Montgomery Scott and
GAMMA Investing purchased large numbers of shares. Regeneron made headlines with a
$200 Million Patient Assistance Match Program for vision care and eye disease treatment, suggesting community outreach. Institutional changes included plans to acquire
23andMe and adopting the technology for faster drug discovery. The pharmaceutical company’s
Q2 2025 financial results announcement and conference call were scheduled. There was also news of the company entering the weight loss market, and them securing a deal for GLP-1/GIP Drug Rights, strengthening its obesity pipeline. However, the crucial
Sanofi-tied failure and reduced expectations from
Citigroup weighed heavily on the stock.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 28 Feb 2025 08:00:00 GMT to Sat, 28 Jun 2025 09:01:25 GMT -
Rating -3
- Innovation 4
- Information 6
- Rumor 2
